Fate Therapeutics (FATE) Expected to Announce Quarterly Earnings on Tuesday

Fate Therapeutics (NASDAQ:FATE) will likely be releasing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Fate Therapeutics to post earnings of ($0.29) per share and revenue of $1.4910 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 14, 2026 at 9:30 AM ET.

Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($0.27) EPS for the quarter, meeting the consensus estimate of ($0.27). Fate Therapeutics had a negative net margin of 2,051.08% and a negative return on equity of 55.02%. The company had revenue of $1.37 million for the quarter, compared to the consensus estimate of $1.20 million. On average, analysts expect Fate Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Fate Therapeutics Price Performance

FATE stock traded up $0.39 during trading on Tuesday, hitting $2.19. 6,272,140 shares of the stock traded hands, compared to its average volume of 1,724,621. Fate Therapeutics has a 1 year low of $0.91 and a 1 year high of $2.25. The firm’s 50 day moving average is $1.29 and its two-hundred day moving average is $1.20. The stock has a market cap of $254.08 million, a price-to-earnings ratio of -1.89 and a beta of 2.13.

Institutional Investors Weigh In On Fate Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. grew its holdings in Fate Therapeutics by 73.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 28,676 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 12,114 shares in the last quarter. Bank of America Corp DE grew its holdings in Fate Therapeutics by 20.0% during the 3rd quarter. Bank of America Corp DE now owns 146,553 shares of the biopharmaceutical company’s stock valued at $185,000 after buying an additional 24,423 shares in the last quarter. Bridgeway Capital Management LLC purchased a new stake in Fate Therapeutics during the 2nd quarter valued at approximately $28,000. Commonwealth Equity Services LLC purchased a new stake in Fate Therapeutics during the 4th quarter valued at approximately $26,000. Finally, Corient Private Wealth LLC purchased a new stake in Fate Therapeutics during the 4th quarter valued at approximately $29,000. 97.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Weiss Ratings cut shares of Fate Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 29th. HC Wainwright increased their price objective on shares of Fate Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday. Three investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Fate Therapeutics presently has an average rating of “Hold” and a consensus price target of $4.50.

About Fate Therapeutics

Fate Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of first?in?class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off?the?shelf natural killer (NK) and T?cell products designed to overcome limitations of donor?derived approaches. Fate’s research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.

Central to Fate’s pipeline are multiple iPSC?derived cell therapy candidates in active clinical development.